<DOC>
	<DOCNO>NCT02581215</DOCNO>
	<brief_summary>This phase II , multicenter , double-blinded , randomize , 2-arm trial evaluate efficacy safety mFOLFIRINOX plus ramucirumab ( Arm A ) vs. mFOLFIRINOX plus placebo ( Arm B ) 94 subject advanced pancreatic cancer , amenable curative treatment . Both arm continue treatment disease progression unacceptable toxicity .</brief_summary>
	<brief_title>Phase II Randomized Trial mFOLFIRINOX +/- Ramucirumab Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . EXPERIMENTAL ARM A : - Oxaliplatin 85 mg/m^2 2-4 hour - Irinotecan 165 mg/m^2 90 minute - 5-FU 2,400 mg/m^2 46-hour continuous infusion without 5-FU bolus decrease risk neutropenia . - Arm A receive ramucirumab ( RAM ) administer intravenous infusion 60 minute ( infusion rate exceed 25 mg/min ) , fix dose 8 mg/kg every 2 week . CONTROL ARM B : - Oxaliplatin 85 mg/m2 2-4 hour - Irinotecan 165 mg/m2 90 minute - 5-FU 2,400 mg/m2 46-hour continuous infusion without 5-FU bolus decrease risk neutropenia . - Arm B receive placebo infusion every 2 week . Due double-blinded nature study , volume placebo calculate RAM . In order demonstrate adequate organ function , screen lab must obtain within 7 day prior registration : Hematological : - Hemoglobin ≥ 9 g/dL - Absolute Neutrophil Count ( ANC ) ≥ 1,500/mm^3 - Platelet Count ( PLT ) ≥ 100,000/mm^3 Renal : - Creatinine ≤ 1.5 mg/dL Creatinine clearance^1 ≥ 40 mL/min - Albumin ≥ 2.5 g/dL Hepatic : - Bilirubin ≤ 1.5 mg/dL - Aspartate aminotransferase ( AST ) ≤ 3 × ULN &lt; 5 xULN set liver metastasis - Alanine aminotransferase ( ALT ) ≤ 3 × ULN &lt; 5 xULN set liver metastasis Coagulation : - International Normalized Ratio ( INR ) ( Patients receive warfarin must switch low molecular weight heparin achieve stable coagulation profile prior first dose protocol therapy ) ≤1.5 partial thromboplastin time ( PTT ) ( PTT/aPTT ) &lt; 1.5 x ULN</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written inform consent Health Insurance Portability Accountability Act ( HIPAA ) authorization release personal health information . . Age ≥ 18 year time consent . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 within 7 day prior registration . Histologic cytological diagnosis recurrent metastatic pancreas adenocarcinoma ( PCA ) present first line chemotherapy treatment . No prior first line systemic treatment ( prior adjuvant neoadjuvant treatment permit ) . Subjects whose disease progress 6 month last systemic chemotherapy chemoradiation adjuvant neoadjuvant set eligible . Measurable disease determine use guideline Response Evaluation Criteria In Solid Tumors ( RECIST 1.1 ) . Baseline tumor assessment perform use high resolution compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) . Urine protein &lt; 1+ dipstick test routine urinalysis . If proteinuria test ≥2+ , 24hour urine test must collect must demonstrate &lt; 1g protein 24 hour allow participation . Estimated life expectancy &gt; 12 week , assess site investigator . If sexually active , must postmenopausal , surgically sterile , use effective contraception ( hormonal barrier method ) due unknown risk teratogenicity ramucirumab Subjects histology adenocarcinoma ; Examples include : neuroendocrine tumor , acinar cell cancer , sarcoma lymphoma pancreas . Ongoing active infection . Symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia . Symptomatic heart failure per New York Heart Association ( NYHA ) Class IIIV . Uncontrolled poorlycontrolled hypertension ( &gt; 160 mmHg systolic &gt; 100 mmHg diastolic &gt; 4 week ) despite standard medical management . Acute subacute intestinal obstruction . Interstitial pneumonia interstitial fibrosis lung , opinion site investigator could compromise subject study . Pleural effusion ascites cause &gt; grade 1 dyspnea . Cirrhosis level ChildPugh B ( bad ) cirrhosis ( degree ) history hepatic encephalopathy clinical meaningful ascites result cirrhosis ; clinically meaningful ascites define ascites result cirrhosis require ongoing treatment diuretic and/or paracentesis . Grade 3 high bleeding event ≤ 3 month prior randomization . Experience arterial thrombotic arterial thromboembolic event , include , limited myocardial infarction , transient ischemic attack , cerebrovascular accident , ≤ 6 month prior randomization . History deep vein thrombosis , pulmonary embolism , significant thromboembolism ( venous port catheter thrombosis superficial venous thrombosis consider `` significant '' ) 3 month prior randomization . Documented and/or symptomatic know brain leptomeningeal metastasis . GI perforation/fistula Documented and/or symptomatic know brain leptomeningeal metastasis . Severely immunecompromised ( steroid ) , include know HIV infection . Concurrent active malignancy adequately treat nonmelanoma skin cancer , noninvasive carcinoma , situ neoplasm . A subject previous history malignancy eligible , provide he/she disease free &gt; 3 year . Breastfeeding pregnant . Prior autologous allogeneic organ tissue transplantation . Known allergy treatment component . Major surgery within 28 day prior first dose protocol therapy , minor surgery/subcutaneous venous access device placement within 7 day prior first dose protocol therapy . The patient elective plan major surgery perform course clinical trial . Any condition permit compliance study schedule include psychological , geographical medical . Receiving medication effect clot ability : warfarin , aspirin ( oncedaily aspirin use maximum dose 325 mg/day permit ) , nonsteroidal antiinflammatory drug ( NSAIDs , include ibuprofen , naproxen , others ) , dipyridamole clopidogrel , similar agent . . Serious nonhealing wound , ulcer , bone fracture within 28 day prior first dose protocol therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>mFOLFIRINOX</keyword>
	<keyword>Ramucirumab</keyword>
</DOC>